Previous studies have indicated gefitinib and erlotinib may provide clinical benefits to EGFR-mutated patients with poor PS (≤2).21-24 Inoue and colleagues has previously reported the outcome of gefitinib treatment in 30 NSCLC patients with mutated EGFR and poor PS (≤2); including 22 patients with a PS of 3-4. This evidence concerns the gene EGFR and non-small cell lung carcinoma.